Core Insights - Medtronic announced three significant milestones in the U.S. aimed at expanding access and flexibility for individuals with type 1 and insulin-requiring type 2 diabetes, including Medicare access for the MiniMed™ 780G system with the Instinct sensor, FDA clearance for its use with ultra rapid-acting insulins, and clearance for use with insulin-requiring type 2 diabetes [1][2][6]. Group 1: Medicare Access - Medicare beneficiaries can now access the MiniMed™ 780G system paired with the Instinct sensor, which is small, thin, and can be worn discreetly for up to 15 days [3][5]. - This milestone enhances sensor choice for Medicare users, who also have access to the Simplera Sync™ and Guardian™ 4 sensors [3]. Group 2: FDA Clearances - The FDA has cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins, such as Fiasp and Lyumjev, providing more flexibility and personalization in diabetes therapy [6]. - The system's Meal Detection™ technology allows for better management of mealtime insulin delivery, accommodating missed or delayed doses [6]. Group 3: Benefits of the MiniMed™ 780G System - The MiniMed™ 780G system automates insulin delivery every five minutes, which helps maintain stable glucose control and reduces the burden of daily decision-making for users [4][9]. - The integration of the Instinct sensor with the MiniMed™ 780G system is expected to improve the daily management experience for individuals with type 2 diabetes [10].